Giao dịch TG Therapeutics, Inc. - TGTX CFD

Điều kiện giao dịch

• Loại: CFD
• Chênh lệch: 0.25
• Điều chỉnh phí tài trợ qua đêm cho vị thế mua: -0.02143%
• Điều chỉnh phí tài trợ qua đêm cho vị thế bán: -0.00079%
• Thời gian điều chỉnh phí tài trợ qua đêm: 21:00 (UTC)
• Tiền tệ: USD
• Số lượng giao dịch tối thiểu: 0.1
• Biên lợi nhuận: 50.00%
• Sàn giao dịch chứng khoán: United States of America
• Phí hoa hồng giao dịch: 0%
• Bảo đảm dừng phí bảo hiểm: 1%

Số liệu thống kê chính

• Trước đó Đóng: 42.58
• Mở: 42.2
• Thay đổi 1 năm: 26.84%
• Phạm vi trong ngày: 41.17 - 42.2

Giao dịch TG Therapeutics, Inc. - TGTX CFD

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton''s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. The company is headquartered in New York, New York.